0000899243-20-030313.txt : 20201103 0000899243-20-030313.hdr.sgml : 20201103 20201103195614 ACCESSION NUMBER: 0000899243-20-030313 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201102 FILED AS OF DATE: 20201103 DATE AS OF CHANGE: 20201103 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Epstein David M. CENTRAL INDEX KEY: 0001488668 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39200 FILM NUMBER: 201284882 MAIL ADDRESS: STREET 1: OSI PHARMACEUTICALS, INC. STREET 2: 41 PINELAWN ROAD CITY: MELVILLE STATE: NY ZIP: 11747 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Black Diamond Therapeutics, Inc. CENTRAL INDEX KEY: 0001701541 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 139 MAIN STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-417-5868 MAIL ADDRESS: STREET 1: 139 MAIN STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Aset Therapeutics, Inc. DATE OF NAME CHANGE: 20170321 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-11-02 0 0001701541 Black Diamond Therapeutics, Inc. BDTX 0001488668 Epstein David M. C/O BLACK DIAMOND THERAPEUTICS, INC. 139 MAIN STREET CAMBRIDGE MA 02142 1 1 0 0 See Remarks Common Stock 2020-11-02 4 M 0 3000 6.42 A 723923 D Common Stock 2020-11-02 4 S 0 11917 31.1329 D 712006 D Common Stock 2020-11-02 4 S 0 83 31.875 D 711923 D Common Stock 23090 I See footnote Common Stock 104449 I See footnote Common Stock 104449 I See footnote Common Stock 16579 I See footnote Common Stock 16579 I See footnote Stock Option (Right to Buy) 6.42 2020-11-02 4 M 0 3000 0.00 D 2029-08-13 Common Stock 3000 238616 D Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.74 to $31.73 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Shares held by wife. Shares held by David M. Epstein 2019 Trust For Elle. David M. Epstein is the trustee of the David M. Epstein 2019 Trust for Elle and may be deemed to beneficially own these securities. Shares held by David M. Epstein 2019 Trust For Zoe. David M. Epstein is the trustee of the David M. Epstein 2019 Trust for Zoe and may be deemed to beneficially own these securities. Shares held by David M. Epstein 2019 Trust For Robert. David M. Epstein is the trustee of the David M. Epstein 2019 Trust for Robert and may be deemed to beneficially own these securities. Shares held by David M. Epstein 2019 Trust For Shelley. David M. Epstein is the trustee of the David M. Epstein 2019 Trust for Shelley and may be deemed to beneficially own these securities. 25% of the shares subject to this option vested and became exercisable on August 14, 2020, with the remainder vesting in 36 equal monthly installments thereafter. Officer Title: President and Chief Executive Officer /s/ Brent Hatzis-Schoch, as Attorney-in-Fact 2020-11-03